Document Detail


Approaches to decongestion in patients with acute decompensated heart failure.
MedLine Citation:
PMID:  23299712     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Loop diuretics remain a mainstay in the pharmacologic treatment of acute decompensated heart failure (ADHF). Recent randomized trial results have challenged existing clinical dogma about the optimal manner of intravenous diuretic administration in hospitalized patients. The Diuretic Optimization Strategies Evaluation (DOSE) trial, while technically a neutral study, suggested some advantages of a high-dose diuretic strategy as compared with low dose administration without evidence of long term safety concerns. The DOSE study additionally showed no difference in efficacy or safety between continuous infusion or bolus diuretic therapy. Venovenous ultrafiltration (UF) holds promise as an alternative approach to volume removal in ADHF, but significant work remains in characterizing the relative risks and benefits of this technique, as well as the degree to which it can be broadly utilized. This review highlights current approaches and future directions in mitigating congestion and volume overload in the ADHF population, with a particular focus on novel diuretic dosing strategies and on the emerging role of UF.
Authors:
Daniel Muñoz; G Michael Felker
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Current cardiology reports     Volume:  15     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-09     Completed Date:  2013-06-25     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  335     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Heart Failure / therapy*
Hemofiltration*
Humans
Sodium Potassium Chloride Symporter Inhibitors / administration & dosage*
Grant Support
ID/Acronym/Agency:
T32 HL007411/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Sodium Potassium Chloride Symporter Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Update on type 2 diabetes as a cardiovascular disease risk equivalent.
Next Document:  Decreased energy density and changes in food selection following Roux-en-Y gastric bypass.